Minimal Residual Disease Testing Market (By Technology; By Cancer Type; By End Use: Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Minimal Residual Disease Testing Market 

5.1. COVID-19 Landscape: Minimal Residual Disease Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Minimal Residual Disease Testing Market, By Technology

8.1. Minimal Residual Disease Testing Market, by Technology, 2022-2030

8.1.1 Next Generation Sequencing (NGS)

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Polymerase Chain Reaction (PCR)

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Flow Cytometry

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Minimal Residual Disease Testing Market, By Cancer Type

9.1. Minimal Residual Disease Testing Market, by Cancer Type, 2022-2030

9.1.1. Haematological Malignancy

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Haematological Malignancy

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Minimal Residual Disease Testing Market, By End use 

10.1. Minimal Residual Disease Testing Market, by End use, 2022-2030

10.1.1. Hospitals & Diagnostic Laboratories

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Academic & Research Institutes

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Minimal Residual Disease Testing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2017-2030)

11.1.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.1.3. Market Revenue and Forecast, by End use (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End use (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End use (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2017-2030)

11.2.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.3. Market Revenue and Forecast, by End use (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End use (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End use (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End use (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End use (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2017-2030)

11.3.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.3. Market Revenue and Forecast, by End use (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End use (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End use (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End use (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End use (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2017-2030)

11.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.3. Market Revenue and Forecast, by End use (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End use (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End use (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End use (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End use (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2017-2030)

11.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.5.3. Market Revenue and Forecast, by End use (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End use (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End use (2017-2030)

Chapter 12. Company Profiles

12.1. Adaptive Biotechnologies Corporation

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bio-Rad Laboratories, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Arup Laboratories

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. F. Hoffmann- La Roche Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Cergentis B.V.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Guardant Health

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. ICON plc

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Laboratory Corporation of America Holdings

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Invivoscribe, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Mission Bio, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms